Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 11, 2022

Aging Biomarker p16 Predicts Risk of Peripheral Neuropathy in Women Receiving Adjuvant Taxanes for Breast Cancer

NPJ breast cancer


Additional Info

NPJ breast cancer
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer
NPJ Breast Cancer 2022 Sep 08;8(1)103, N Mitin, KA Nyrop, SL Strum, A Knecht, LA Carey, KE Reeder-Hayes, E Claire Dees, TA Jolly, GG Kimmick, MS Karuturi, RE Reinbolt, JC Speca, EA O'Hare, HB Muss

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading